Article
Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Molecular cancer - 6 Nov 2023
Roussel-Simonin Cyril, Blanc-Durand Felix, Tang Roseline, Vasseur Damien, Le Formal Audrey, Chardin Laure, Yaniz Elisa, Gouy Sébastien, Maulard Amandine, Scherier Stéphanie, Sanson Claire, Lacroix Ludovic, Cotteret Sophie, Mauny Lea, Zaccarini François, Rouleau Etienne, Leary Alexandra
Abstract excerpt
BACKGROUND: Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15-19% of cases. Peritoneal fluid, available in > 95% of advanced EOC cases, could serve as an alternative source of cell-free tumor DNA...
Topics
Join the communities discussing this publication.